drugset / Trial / NCT01472380

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380

Phase 1 Completed 30 enrolled Mutual Pharmaceutical Company, Inc.
Non-randomizedSingle-groupOpen-labelBasic science

Summary

Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects.

Timeline

Start
2011-11
Primary completion
2011-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg Oral
Comparator fenofibric acid Small molecule 105 mg Oral

Indications

No indication recorded.